study question: Is polycystic ovary morphology (PCOM) associated with metabolic syndrome (MS), insulin resistance (IR) and dyslipidemia? summary answer: No associations between PCOM and metabolic disorders were found. what is known already: Polycystic ovary morphology has a prevalence of 21-63% in healthy women of reproductive age. Results of studies focusing on metabolic abnormalities among females with PCOM, are insufficient and controversial. study design, size, duration: This was a cross-sectional population-based study from five provinces in Iran. A standard questionnaire was filled out during face-to-face interviews and clinical examinations were done. All study subjects were invited to undergo blood sampling and ultrasonographic assessment.
Introduction
Polycystic ovary syndrome (PCOS) is the most common cause of endocrine dysfunction in women between the ages of 18 and 45 and has a prevalence of 4 -10% (Knochenhauer et al., 1998; Asuncion et al., 2000) . PCOS was initially diagnosed in women with menstrual irregularity and hyperandrogenism (Stein and Leventhal, 1935) and later the ultrasound criterion for polycystic ovary morphology (PCOM) was included in the Rotterdam Criteria (2004) and was also recommended by the National Institutes of Health (NIH) (2012) .
PCOM is defined as enlarged ovarian volume and or an increased follicular number (Dewailly et al., 2014) . PCOM in healthy women is seldom considered an endocrinopathy, however it is believed that it is associated with some PCOS-related features (Adams et al., 2004; Mortensen et al., 2009) . This morphology has been documented in 21-63% of asymptomatic women (Catteau-Jonard et al., 2012) .
Endocrine profiles of women with only PCOM have been investigated in several studies (Adams et al., 2004; Legro et al., 2005; Yildiz et al., 2012) and abnormal gonadotrophin levels and increased 17-Hydroxyprogesterone (17-OHP) were repeatedly reported in this population (Norman et al., 1995) . Some studies reported that the testosterone and androstenedione (A 4 ) levels observed in women with PCOM were within the normal range but still higher than women with normal ovarian morphology. Differences in gonadotrophin dynamics have also been observed (Adams et al., 2004; Carmina et al., 2005) . Thus ovulatory women with PCOM may be at the mildest end of the spectrum of PCOS.
Few studies investigated the association of PCOM with cardiovascular and metabolic disorders. Engin-Ustün et al. found that women with PCOM have higher serum C-reactive protein levels than healthy controls (Engin-Ustun et al., 2006) . This may contribute to increased cardiovascular disease risk in patients with PCOM. Cenk Sayin et al. showed similar metabolic characteristics in women with PCOM and those with PCOS (Cenk Sayin et al., 2003) . Adams et al. suggested that ovulatory women with PCOM have higher insulin resistance (IR) than women with normal ovarian morphology (Adams et al., 2004) , Loucks et al. however concluded that PCOM does not seem to further intensify cardiovascular disease risk profiles in women affected by PCOS (Loucks et al., 2000) . This heterogeneity of results was not conclusive due to small sample sizes, differences in subjects' ethnicity and lifestyles, and study design. Hence the significance of this symptom is still controversial among reproductive aged women (Yildiz et al., 2012) and the question remains on whether women with PCOM are at mild risk of PCOS or they should be considered healthy (Dewailly et al., 2014) .
In this study, we aimed to determine the risks of metabolic syndrome components, IR and dyslipidemia in women with PCOM, compared with healthy women. The community-based nature of our study and its adequate large sample size may give us the opportunity of providing a better understanding of these correlations.
Materials and Methods

Population and participants
This study was conducted on data collected for two studies, the Iranian PCOS prevalence study and the Khouzestan PCOS prevalence study (Rashidi et al., 2014) . The details of these studies were previously published. Iranian PCOS prevalence study was conducted on 1126 women. These women were randomly recruited from four previously selected provinces of different geographical characteristics in Iran . The Khouzestan PCOS prevalence study had a total number of 646 women, aged from 18 to 45 years (Rashidi et al., 2014) , as thus study flowchart shows (Fig. 1) . Reproductive aged women living in urban areas of these provinces were recruited using a stratified multistage probability cluster sampling method. Less than 10% (n ¼ 92) of invited women refused to participate. We have no information on them to compare with data of participants enrolled. The two original groups did not significantly differ in composition. Mean ages of participants of the Iranian and Khouzestan PCOS prevalence studies were 34.3 + 7.6 and 33.2 + 7.8 years old, respectively. Mean body mass index (BMI) was 26.8 + 5.0 kg/m 2 in the first and 26.6 + 5.0 in the second study. Mean education years in four provinces was 8.9 + 4.4 years while in the fifth province it was 10.1 + 4.3 years.
Ethical approval
The ethical review board of the Research Institute for Endocrine Sciences approved the study proposal, and written informed consent was obtained from each subject.
Participant assessment
Each participant completed a questionnaire during a face-to-face interview with trained midwives under supervision of a gynecologist. Blood pressure (BP), anthropometric, hormonal and metabolic measurements were collected and all participants underwent transvaginal (82.43%) scan or transabdominal (17.57%) ultrasonography of the ovaries using the 3.5-MHz transabdominal and 5-MHz transvaginal transducer, respectively. Ultrasound was performed on the same day as blood samples were collected which was scheduled for the second or third day of participants' spontaneous or progesterone induced menstrual cycle. All ultrasound equipment selected for these studies were the same with 3.5-MHz for transabdominal and 5-MHz for transvaginal transducer. A sonographer in each province performed the ultrasound and the ultrasonographic images were sent to an expert sonologist for confirmation.
Paraclinical measurements
Dehydroepiandrosterone sulfate (DHEAS) was measured by enzyme immunoassay (EIA) (DRG Instruments, GmbH, Germany); 17OHP, total testosterone (TT), and A4 were measured by enzyme immunoassay (EIA) (Diagnostic biochem Canada Co. Ontario, Canada). Sex hormone binding globulin (SHBG) was measured by immunoenzymometric assay (IEMA) (Diagnostic biochem Canada Co. Ontario, Canada). All ELISA tests were performed using the Sunrise ELISA reader (Tecan Co. Salzburg, Austria). Luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin (PRL), and thyroid stimulating hormone (TSH) were measured by immunoradiometric assay (IRMA) (Izotop, Budapest, Hungary) using a gamma counter (Dream Gamma-10 gamma counter, Shin Jin, Korea). Insulin was measured by immunoenzymometric assay (IEMA) (Mercodia, Uppsala, Sweden). Glucose, triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL) and high density lipoprotein (HDL) were measured by enzymatic colorimetery (Pars Amazon Co. Tehran, Iran). Homeostatic model assessment for insulin resistance (HOMA-IR) was calculated as fasting insulin (mIU/l) * fasting blood sugar (FBS) (mg/dl)/405. The intra-and inter-assay coefficients of variation for TT were 1.7 and 2.3%, respectively, DHEAS-1.9 and 2.5%, 17OHP-4.8 and 6.8%, SHBG-0.8 and 2.4%, A4-4.5 and 6.8%, LH-1.6 and 4.2%, FSH-1.4 and 2%, TSH-2.1 and 3.1%, PRL-2.3 and 3.5%, Ins-0.9 and 1.1%, Glucose-1.3 and 2.9%, TG-1.8 and 2.7%, TC-0.8 and 2.8%, LDL-0.7 and 2.9%, and HDL, they were 0.9 and 3.3%, respectively. Women with either androgen excess per se (n ¼ 347) or ovulatory dysfunction (n ¼ 112) and those with PCOS (n ¼ 223) by Rotterdam (Rott) criteria were excluded. Therefore, our study sample size was 809. These women were categorized into two groups, women with only PCOM (n ¼ 126) and healthy controls (n ¼ 683).
Definitions
PCOM was mainly defined as having polycystic ovaries with 12 or more follicles in each ovary, measuring 2 -9 mm in diameter and/or increased ovarian volume (10 cm 3 ). While there were only 3 women, out of 809 participants who had undergone transabdominal sonographic scans, we re-classified our study population according to increased ovarian volume (10 cm 3 ), to omit the possible effect of not using the high resolution ultra sonography or using transabdominal approach; this classification resulted in 74 women with PCOM and 735 healthy ones.
Metabolic syndrome (MS) was defined based on the Joint Interim Statement (JIS) and diagnosed according to the presence of at least three of the following criteria (Alberti et al., 2009) 
Statistical analyses
Continuous variables were expressed as mean and standard deviation (SD) and categorical variables as percentages. ANCOVA analyses were used to determine the mean difference between continuous variables, after adjusting for age and BMI. Chi-square tests were used to compare the prevalence of MS, IR and dyslipidemia between PCOM and the controls. Logistic regression models were designed to assess the association between PCOM and development of MS, IR and dyslipidemia adjusting for age, BMI, TSH and androgenic hormones. Data were analyzed by SPSS version 15 (SPSS Inc., Chicago, IL, USA), and statistical significance was set at P , 0.05.
Results
One hundred and twenty-six women in the PCOM group and 683 women in the control group completed the study procedure with the response rate of 100%. PCOM group and controls were on average (mean + SD) 34.0 + 7.3 and 35.1 + 7.5 years old, respectively. Sixtyone percent of women with PCOM and 60.8% of the control group had BMI ≥ 25 kg/m 2 while 21.4% of women with PCOM were obese (BMI ≥ 30 kg/m 2 ) compared with 23% in control group. There were no observed statistical differences between the two groups in age or BMI. ANCOVA analyses adjusted for age and BMI showed that the HDL level (47.4 + 11.0 mg/dl versus 44.9 + 11.8 mg/dl, P ¼ 0.05), SBP (112.1 + 12.9 mmHg versus 108.4 + 15.1 mmHg, P ¼ 0.004) and A 4 (1.46 + 0.49 ng/ml versus 1.29 + 0.49, P ¼ 0.008) were significantly higher in the PCOM group compared with their healthy counterparts, despite all values being within normal ranges (Table I) . Demographic and reproductive characteristics and metabolic and hormonal status of women with and without PCOM are shown in Table I after adjusting  for age and BMI. Among women with PCOM, 54% had HDL , 50 mg/dl, a prevalence significantly lower than the normal group (P ¼ 0.03). However SBP . 130 mmHg was significantly higher in the affected women ( 2.9%, P ¼ 0.01). Prevalence of metabolic disorders among the two groups were assessed and summarized in Table II .
Comparing the prevalence of MS, IR and dyslipidemia between the two groups, using chi-square tests revealed that only dyslipidemia was significantly higher among the control group (29.9 versus 19.0%, P ¼ 0.01) and MS and IR were not significantly different. According to our results, 32.5% of women with PCOM had only one component of MS, 51.6% two components and 15.1% three or more components.
However these were observed in 34.0, 48.8 and 16.8% of controls, respectively and there were no significant differences between the two groups (P ¼ 0.62).
Logistic regression analyses demonstrated that there were no significant associations between MS, IR and dyslipidemia and PCOM after adjusting for age, BMI, TSH and serum levels of androgens (Table III) .
Re-classification of the study population, based on increased ovarian volume caused no changes in metabolic results (Supplementary Tables  SI -SIII) .
Discussion
Based on our results, development of MS, IR and dyslipidemia after adjusting for metabolic parameters were not significantly associated with PCOM, though dyslipidemia had significantly higher prevalence among controls. Comparing MS and its components in the two groups showed that serum HDL tends to be higher in women with PCOM, while other metabolic parameters were not significantly different between the two groups.
Studies on phenotypes of PCOS show that androgen excess aggravates metabolic abnormalities in women with PCOS (Carmina et al., 2005; Barber et al., 2007; Sung et al., 2014) . Chang et al. found that increased secretion of LH and FSH in response to stimulation of GnRH by agonists leads to 30% higher levels of ovarian androgens among women with PCOM compared with controls while gonadotrophin and androgen values were similar in PCOM and normal women at baseline (Chang et al., 2000) . These findings are in support of our results since in our population we found no significant association between MS, dyslipidemia and IR and PCOM. Moreover it has been reported that recent ultrasound technology advancements facilitate the detection of small antral follicles which may incorrectly reflect an increase in percentage of PCOM (Catteau-Jonard et al., 2012) . Considering that there is 21 -63% prevalence of PCOM among healthy women, biochemical and metabolic characteristics of women with PCOM seem more similar to normal women compared with women with PCOS. The mechanism by which PCOM and or hyperandrogenism contribute to cardiovascular risk factors has not been accurately elucidated. One study found raised cardiovascular risk factors among women with PCOM who had hyperandrogenism, compared with women with idiopathic hyperandrogenism, suggesting the possible independent role of PCOM (Carmina et al., 2005) . However, of women with various PCOS phenotypes those who do not meet hyperandrogenism criteria, are often considered the mildest group of affected women with the lowest cardiovascular risk profile, indicating likelihood of androgenic effects (Jovanovic et al., 2010) . Consistent with the results of the two mentioned studies, our results also show no dramatic effect for PCOM or androgenic serum levels on development of metabolic abnormalities.
MS is reported to be more prevalent among women with PCOS (46%) compared with healthy female population (23%) which was previously reported to be associated with ethnicity and life style factors (Jovanovic et al., 2010) . Using factor analysis, Sung et al. showed that PCOM may not be related to metabolic disorders. This could be the reason for it not being considered a distinct criterion of PCOS (Sung et al., 2014) . Other mechanisms suggested for the higher rates of metabolic disorders among women with PCOS are hyperinsulinemia and IR (Teede et al., 2010) which are not significantly different between our two groups. While mean HOMA-IR did not differ between women with and without PCOM, 16.7% of women with PCOM developed IR. Similar to our findings, Michelmore et al. found no significant difference in fasting serum level of insulin and insulin sensitivity using HOMA-IR; however fasting serum level of insulin has been reported to contribute to changes in ovarian morphology, such as PCOM (Michelmore et al., 1999) and also as both the possible cause and effect of PCOS through several mechanisms (Teede et al., 2010) . Since our study population did not have hyperandrogenism and menstrual irregularity, the results suggests that PCOM did not affect IR nor was it affected by it.
HDL , 35 mg/dl was seen in 11.1% of the PCOM group; however, serum level of HDL as a component of MS and dyslipidemia in our study was higher among women with PCOM compared with normal ones. Dyslipidemia also had a slight significant association with TSH serum level. HDL , 35 mg/dl is 20 mg/dl below the reported mean level among white women and is considered as an important cardiovascular risk factor (Chang et al., 2000) . HDL serum level has been demonstrated to be lower in PCOS patients (Chang et al., 2000; Diamanti-Kandarakis E1, 2007) and lower or normal in women with PCOM in comparison with normal controls (Chang et al., 2000; Adams et al., 2004; Murphy et al., 2006) , findings contrary to ours. However, consistent with our results, two other studies found HDL levels to be higher in women with PCOM compared with women with PCOS (Norman et al., 1995; Cenk Sayin et al., 2003) . Thyroid disorders are also reported to be more prevalent among women with PCOS (Gaberscek et al., 2015) and can affect metabolism and hence contribute to dyslipidemia even among women with subclinical forms (Yetkin and Dogantekin, 2015) . The metabolic results might be affected by different age, BMI and androgen levels in addition to ethnicity and life styles in various study groups. Had our study population been younger, the risk of metabolic disorders would have been different.
In the present study A 4 was the only androgen significantly higher among women with PCOM, though their serum level of DHEAS and SHBG tend to be slightly higher and lower, respectively. It has been previously reported that normal range women with PCOM may show higher serum levels of androgens compared with normal healthy women (Jovanovic et al., 2010) . Among women with PCOM, testosterone bioavailability as a result of decreased SHBG was reported to be increased (Michelmore et al., 1999) ; however with aging, serum levels of testosterone and SHBG are expected to decline and rise, respectively (Loucks et al., 2000) .
SBP was another MS component that was significantly higher in the PCOM group compared with controls. It has been shown that 40% of women with PCOS will have hypertension by their premenopausal period (Chang et al., 2000) . A study of young women whose mothers had PCOS found insignificant and significant higher SBP and DBP among PCOM compared with completely normal healthy group (Battaglia et al., 2009 ). Higher SBP among affected women may represent the onset of a cascade of changes into cardiovascular diseases that may be observed in later age, demonstrating a need for periodical surveillance.
As expected, in our study BMI had a significant association with metabolic syndrome, insulin resistance and dyslipidemia; nevertheless it should be mentioned that increased cardiovascular risk factors have even been found among women with PCOS, who were not obese (Jovanovic et al., 2010) .
The present study is the first community-based study conducted on Iranian women, aimed at assessing the metabolic disorders among women with PCOM. Ultrasonographic assessment was done for all study population and in order to enhance the accuracy of results related to PCOM, other PCOS components including isolated hyperandrogenism and isolated anovulation were strictly excluded. National Iranian cut off values for WC and HOMA-IR were used and although age and BMI were not significantly different between the two groups, we adjusted them as possible confounders of cardiovascular disease risk factors to account for a more consistent cohort of women. Since TSH level can affect the metabolic profile, in addition to main confounding variables assessed in various studies, we included TSH in the regression models. Limitations of the study are as follow: we did not measure serum concentrations of progesterone in the luteal phase, which determines subclinical anovulation, although using mass spectrometry-based assays is strongly recommended for measuring androgenic status, due to budget limitations we had to use EIA and we used the older ultrasound technology (5 MHz) and PCOM definition, as our study has been conducted before the task force recommendation for using a threshold of ≥25 follicle number per ovary for the definition of PCOM when using transducer frequency ≥8 MHz or ovarian volume if such technology is not available (Dewailly et al., 2014) . However re-classification of our study participants according to the ovarian volume did not affect the metabolic results.
In conclusion, our study found no significant association between metabolic disorders and PCOM, and hence lacked the evidence needed for inclusion of PCOM in the main PCOS diagnostic criteria. To further clarify the association between PCOM and present and longterm metabolic disorders, longitudinal prospective studies considering participants' genetic and environmental background are recommended.
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